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OBJECTIVES The Circadian Anti-ischemia Program in Europe (CAPE II) compared the efficacy of
amlodipine and diltiazem (Adizem XL) and the combination of amlodipine/atenolol and
diltiazem (Adizem XL)/isosorbide 5-mononitrate on exercise and ambulatory myocardial
ischemia during regular therapy and after omission of medication.
BACKGROUND The optimal medical therapy for ischemia suppression and the impact of irregular dosing
using agents with different pharmacologic properties has not been established in patients with
coronary disease.
METHODS Patients with 4 ischemic episodes or 20 min of ST segment depression on 72-h
electrocardiogram were randomized to amlodipine 10 mg once daily or diltiazem (Adizem
XL) 300 mg once daily in a 14-week double-blind randomized multicountry study. In the
second phase, atenolol 100 mg was added to amlodipine and isosorbide 5-mononitrate 100
mg to diltiazem (Adizem XL). Ambulatory monitoring (72 h) and exercise testing were
repeated after both phases, on treatment and after a 24-h drug-free interval.
RESULTS Both monotherapy with amlodipine and diltiazem (Adizem XL) were effective on symptoms
and ambulatory and exercise ischemia. Combination therapy reduced ischemia further, with
amlodipine/atenolol superior to diltiazem (Adizem XL)/isosorbide 5-mononitrate. Amlodipine/
atenolol was significantly superior during the drug-free interval with maintenance of ischemia
reduction.
CONCLUSIONS Amlodipine, with its intrinsically long half-life alone or together with beta-blocker, is likely
to produce superior ischemia reduction in clinical practice when patients frequently forget to
take medication or dose irregularly. (J Am Coll Cardiol 2002;40:917–25) © 2002 by the
American College of Cardiology Foundation
Transient myocardial ischemia in patients with coronary
artery disease (CAD) occurs frequently during daily life and
has been linked to increased morbidity and mortality (1).
Only a proportion of ischemic episodes are accompanied by
angina pectoris, and the activity, characteristics, and circa-
dian distribution of ischemia can be determined using ST
segment ambulatory electrocardiogram (ECG) monitoring
(2).
Numerous studies have shown a complex pathophysiol-
ogy for ischemic events, not determined simply by an
increase in myocardial demand, and a characteristic circa-
dian pattern with a peak incidence in the early morning
hours similar to that seen for myocardial infarction (MI)
and sudden death (3,4). These findings have led to the
development of drugs that are effective for 24 h when given
once daily and that target the disturbed vascular pathophys-
iology responsible for transient myocardial ischemia during
the patient’s daily activities.
The Circadian Anti-ischemia Program in Europe
(CAPE) study demonstrated that amlodipine, a once-a-day
dihydropyridine calcium channel blocking agent with an
intrinsically long half-life, significantly reduced angina and
ischemia over 24 h when added to background medication
(5). These results contrasted with the earlier disappointing
findings using first-generation short-acting dihydropyridine
agents (6), but left several questions unanswered. In the
CAPE study, approximately two-thirds of patients were
receiving beta-blockers and, consequently, the impact of
monotherapy with amlodipine could not adequately be
assessed. Furthermore, the study was not designed to
compare the efficacy of combination regimes widely used in
clinical practice. It is well known that patients frequently do
not comply with prescribing instructions, taking their med-
ication at variable intervals or omitting doses completely.
Irregular dosing in this way is known to affect blood
pressure control and hypertension, but its impact on angina
and transient myocardial ischemia in coronary patients has
not been adequately evaluated (7,8). The CAPE II study
was a multinational collaborative study in Europe, designed
to address these issues in a large population of patients with
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stable angina and CAD. The effect of an intrinsically
long-acting dihydropyridine, amlodipine, was compared to
diltiazem (Adizem XL), a benzothiazepine calcium channel
blocker, which can be dosed once daily through an extended
delivery system. The combination of amlodipine with a
beta-blocker (atenolol) was then compared to diltiazem
(Adizem XL) with isosorbide 5-mononitrate. These drug
combinations are some of the most widely used treatments
for patients with coronary disease and stable angina pectoris.
For both monotherapy and combination phases, the anti-
ischemic efficacy was assessed after regular dosing adminis-
tration and following omission of a single dose, simulating
the situation frequently encountered in clinical practice.
METHODS
Patients. Patients were recruited in 30 centers in 13 coun-
tries (see Appendix). Men and women age 21 to 80 years
were screened if they had a history of stable angina (2
attacks per week, with no change in symptoms for 1
month, a positive exercise test together with at least one
other objective indicator of coronary disease (thallium ex-
ercise test, coronary arteriogram demonstrating 70% ste-
nosis of at least one major coronary artery, previous MI 2
months before screening based on history, ECG and/or
enzyme changes, history of revascularization by coronary
artery bypass surgery or angioplasty). Arteriography dem-
onstrating occlusive coronary disease was an entry criterion
for women because of the reduced specificity of ST segment
changes during ambulatory ECG monitoring and exercise
testing as markers of myocardial ischemia when compared
to males.
Patients were excluded if they had congestive cardiac
failure, uncontrolled arrhythmia or hypertension, standing
systolic blood pressure (BP) 100 mm Hg, heart rate 50
beats/min, greater than first-degree atrioventricular block,
or any ECG feature that would interfere with interpretation
of ST segment changes. All patients gave written informed
consent as approved by the institutional review boards of the
individual study sites. Suitable patients on the basis of these
clinical criteria underwent 72 h of continuous ambulatory
ECG monitoring. If they had a total of 20 min of
transient ST segment depression or4 ischemic events they
were randomized to the active phase of the study. The ST
segment was measured 80 ms after the J point and an
episode was recorded if there was 1 mm of horizontal or
downsloping ST depression for 1 min with 1 min
separating episodes. The duration of each episode was
defined as the interval between the initial 1-mm ST
segment depression at the start of the episode and the time
at which the ST segment depression became 1 mm for
60 s at the end of the episode. Patients were maintained on
stable doses of all concomitant cardiovascular medications
(if any) throughout the study; only those who had received
calcium channel blockers within the week before entry were
excluded. Patients were instructed to take sublingual nitro-
glycerin for episodes of angina pectoris, but not for prophy-
laxis. In addition, open-labeled nitroglycerin tablets were
provided to ensure nonexpired medication.
Study design (Fig. 1). During a two-week, single-blind
placebo run-in, patients underwent ambulatory ECG mon-
itoring and exercise testing. Suitable patients were then
randomized to receive six weeks of treatment with either 5
mg amlodipine or 180 mg diltiazem (Adizem XL) (phase 2)
once daily. The study medication was administered in a
blinded manner using a double-dummy design. After two
weeks of treatment, the doses of medication were adjusted
to amlodipine 10 mg or diltiazem (Adizem XL) 300 mg
unless this was deemed inappropriate by the clinician. At
the end of phase 2, 72-h ambulatory ECG monitoring and
exercise testing were repeated in an identical fashion to the
initial evaluation. On the third day of ambulatory ECG
monitoring, both study groups were given placebo medica-
tion to simulate the omission of a single drug dose against
the background of previously stable active therapy. Exercise
testing was performed both on and after omission of the
drug.
A blinded, six-week active combination phase (phase 3)
was then undertaken with 50 mg of atenolol once daily
given to the patients receiving amlodipine and 50 mg of
isosorbide 5-mononitrate once daily to those receiving
diltiazem (Adizem XL). After two weeks, the doses of
atenolol and 5-mononitrate were each increased to 100 mg
unless clinically contraindicated. At the end of phase 3, 72-h
ambulatory ECG monitoring and exercise testing were
again repeated in a manner identical to the evaluation at the
end of phase 2. Throughout the study, patients were
instructed to record episodes of angina/sublingual nitroglyc-
erin consumption and side effects in a structured diary.
Ambulatory ECG monitoring. Oxford Medilog 2 channel
recorders (modified V3 lead for channel 1 and V5 or lead II
for channel 2) were used for ST segment monitoring at all
sites. Each tape was calibrated with a 0.1 MV signal and
seven positional maneuvers were performed at the start of
each 24-h period. Tapes were analyzed centrally at a core
laboratory by a single technician, with each record overread
in a blinded fashion by one experienced cardiologist (5). If
the patients’ screening tapes fulfilled the ischemia criteria
for inclusion, the investigators were informed within 48 h to
enable timely randomization to phase 2. An alert system was
also employed so that the treating physician could be made
aware of findings that might require clinical intervention
(such as arrhythmia).
Each 24-h recording was analyzed on an Oxford Medilog
Abbreviations and Acronyms
BP  blood pressure
CAD  coronary artery disease
CAPE  Circadian Anti-ischemia Program in Europe
ECG  electrocardiogram
MI  myocardial infarction
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Excel Analyzer for episodes of ST segment depression. ST
segment elevation was very rare and was not included in the
analysis. A minimum of 18 h of technically satisfactory
signal per 24-h recording was required for inclusion in the
final analysis. For each 24-h tape the number, duration, and
peak depression of ST episodes and their time was noted.
The presence or absence of chest pain was determined by a
patient-activated event marker.
Exercise testing. Exercise testing was performed using a
protocol of standard graded increase in workload (20-watt
steps with 2-min increments) on a bicycle ergometer. Heart
rate and blood pressure were monitored for each stage and
the following measurements were made for each test: time
to onset of 1-mm ST segment depression, double product at
onset 1-mm ST segment depression, time to onset of
angina, total workload, total exercise time, and reasons for
stopping exercise. Testing was performed at the same time
of day 2 h after the previous meal and 1 h after
consumption of sublingual nitroglycerin. All exercise ECG
records were analyzed by a core laboratory using standard-
ized criteria by two experienced cardiologists (9).
Angina diaries. Patients completed standardized daily an-
gina diaries during the whole trial period in which they
recorded attacks of angina and consumption of sublingual
nitroglycerin. The individual investigators recorded adverse
events after nondirected patient enquiry throughout the
trial. These were recorded in the study case records, and
serious events were communicated to the sponsor within
24 h.
Analysis. The primary efficacy measurements were from
the ambulatory ECG records and included: 1) total number
of ST-segment episodes; 2) total duration of ST-segment
episodes; and 3) peak ST segment depression during the
48-h monitoring on active therapy. The change from
baseline at the end of monotherapy (week 8) and combina-
tion therapy (week 14) in each of these variables was
analyzed using the Wilcoxon rank-sum test for between-
treatment comparisons and the Wilcoxon signed-rank test
for within-treatment comparisons. The mean change from
baseline was analyzed for both on (first 48 h with active
study medication) and off (last 24 h with placebo) study
drug. The “drug holiday” (off) effect during monotherapy
and combination therapy treatment periods was also ana-
lyzed over the entire 24 h and last 8 h of the Holter
monitoring period, respectively.
Secondary efficacy measures were the 24-h ambulatory
ECG records off medication, the exercise test measure-
ments, and the daily diary data. Analysis of variance models
were used to compare treatment groups across phases.
These included main effects (such as treatment group and
center) as well as interaction effects (such as treatment
groups by center). This analysis was performed on the
change from baseline for each exercise parameter. If the
center-by-treatment interaction was not statistically signif-
Figure 1. Study design.
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icant, a reduced model excluding the interaction term was to
be used. Type III sum of squares was used for all hypotheses
tested in each of the statistical models. Times to event
variables (time to onset of angina and ST segment) were
analyzed using paired t tests. Pearson’s chi-square test was
used to compare treatment groups with respect to binary
variables.
RESULTS
Patient data (Table 1). Of 513 patients screened, 250
(49%) were randomized to phase 2 and 128 received
amlodipine and 122 diltiazem (Adizem XL). There were no
significant differences in age, gender, angina history, inci-
dence of previous MI or revascularization, heart rate, or
blood pressure between the two groups. The majority of the
patients were receiving aspirin and angiotensin-converting
enzyme inhibitors. In addition, both groups commonly used
lipid-lowering drugs.
One hundred twenty-two of 128 patients (98%) com-
pleted both the amlodipine monotherapy (phase 2) and
amlodipine/atenolol combination (phase 3) stages, whereas
110 of 122 (90%) completed the diltiazem (Adizem XL)
monotherapy and diltiazem (Adizem XL)/isosorbide
5-mononitrate combination stages. One patient died during
phase 2 (in the diltiazem [Adizem XL] group), withdrawal
because of adverse events (see later) occurred in five patients
on amlodipine and two patients on diltiazem (Adizem XL)
in phase 2, and in one patient on amlodipine/atenolol and
two patients on diltiazem (Adizem XL)/5-mononitrate in
phase 3. The remaining discontinuations were for reasons
other than adverse events.
Titration of drug to the maximum specified dose was
successfully achieved in the great majority of patients so that
by the end of phase 2, the mean dose of amlodipine was 9.5
mg and diltiazem (Adizem XL) 292.9 mg. Similarly, in the
combination phase, the mean dose of atenolol was 89.8 mg
(with 9.3 mg of amlodipine) and 5-mononitrate 91.9 mg
(with 292.5 mg of diltiazem [Adizem XL]).
Monotherapy phase (phase 2). AMBULATORY ECG MONI-
TORING. Fully evaluable ambulatory ECG recordings were
obtained in 236 of 250 (94%) of patients (120/128 for
amlodipine and 116/122 for diltiazem [Adizem XL]).
There was no significant difference in baseline ischemia
characteristics between the amlodipine and diltiazem
(Adizem XL) patients. Both drugs as monotherapy resulted
in significant reduction in episodes of transient ST segment
depression with no significant difference in efficacy between
the two treatments (Fig. 2). There was a marked difference,
however, during the third day of ambulatory ECG moni-
toring, during which the patients received placebo (“drug
holiday”). There was maintenance of anti-ischemic efficacy
in the amlodipine-treated patients, whereas those in the
diltiazem (Adizem XL) group showed significantly higher
number (p  0.0001), duration (p  0.0002), and peak ST
depression (p  0.0001) (Fig. 2). The difference between
these responses and “withdrawal” of a single dose of drug
between amlodipine and diltiazem (Adizem XL) treated
patients was highly significant for all ischemia parameters
(p’s  0.002).
At initial monitoring, the well-known circadian pattern
in ischemic activity was present in both groups. Amlodipine
and diltiazem (Adizem XL) monotherapy both reduced
ischemic activity over 24 h with maintenance of the circa-
dian variation. During the “drug holiday” third day of
monitoring, there was a significant difference in circadian
pattern between the two treatment groups. Those who had
received amlodipine showed maintenance of ischemia re-
duction throughout the drug-free 24-h period (drug holiday
effect p  0.92), whereas those who had been receiving
diltiazem (Adizem XL) showed loss of efficacy with levels of
ischemia comparable to of those found at baseline (drug
holiday effect p  0.0001) (Fig. 3A).
Table 1. Demographic and Baseline Characteristics
Amlodipine Diltiazem (Adizem XL)
Characteristic Men Women Total Men Women Total
Number of patients 108 20 128 109 13 122
Age distribution (yrs)
36–45 6 0 6 3 0 3
46–55 27 2 29 31 2 33
56–65 45 11 56 39 9 48
66–75 27 6 33 34 2 36
75 3 1 4 2 0 2
Mean age (yrs) 60.0 62.9 60.5 60.6 60.7 60.6
Age range (yrs) 42–79 54–76 42–79 42–78 47–74 42–78
Race distribution
White 106 20 126 108 13 121
Asian 2 0 2 0 0 0
Other 0 0 0 1 0 1
Mean body weight (kg) 80.7 68.4 — 80.3 72.3 —
Body weight range (kg) 58–109 52–83 — 59–106 61–94 —
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EXERCISE TESTING. The exercise testing results were con-
sistent with those of ambulatory ST segment monitoring.
Both amlodipine and diltiazem (Adizem XL) produced
significant improvement in exercise-induced ischemia (time
to 1 m ST depression 430 to 477 s for amlodipine vs. 428 to
477 s for diltiazem (Adizem XL), p’s 0.01). However, on the
drug holiday day there was significantly less effect with a lower
ischemia threshold in the diltiazem (Adizem XL) group
compared to those who had been receiving amlodipine (p 
0.03) for time to onset of 1 mm ST segment depression (474
s after amlodipine vs. 443 s after diltiazem).
Combination phase (phase 3). AMBULATORY ST SEGMENT
MONITORING. Fully evaluable data for the combination
phase was obtained in 121 patients receiving amlodipine
and atenolol and 109 receiving diltiazem (Adizem XL) and
isosorbide 5-mononitrate. The addition of atenolol to am-
lodipine produced a further significant reduction in all
ambulatory ECG monitoring measures of ischemia (p’s 
0.0001 for number, duration, and peak ST segment depres-
sion). The addition of isosorbide 5-mononitrate to dilti-
azem (Adizem XL) produced a small reduction in these
ischemia measures, but none reached statistical significance.
Comparison between the two treatment groups revealed
that the amlodipine/atenolol patients had the least ambu-
latory ischemia (p  0.01).
During the drug holiday day, as in the monotherapy
phase, the amlodipine/atenolol group had less ischemia than
the diltiazem (Adizem XL)/isosorbide 5-mononitrate
group, with significantly fewer ST segment depression
episodes (p  0.02) and peak ST segment depression (p 
0.02).
Addition of atenolol to amlodipine produced a reduction
in ischemia over the 24-h period (p  0.001). During the
drug-free day the circadian pattern of ischemia was virtually
identical to that seen during the drug-free day after the
monotherapy phase (p  ns). In contrast, the diltiazem
(Adizem XL) isosorbide 5-mononitrate combination
showed a modest circadian benefit compared to the dilti-
azem (Adizem XL) monotherapy phase (p  ns), and there
was rebound to baseline levels of ischemia during the
drug-free day, particularly in the early morning hours and
little benefit beyond (Fig. 3B).
EXERCISE TESTING. The differences between the two com-
bination regimes on exercise testing measures of ischemia
were significant and again consistent with the results of
ambulatory monitoring. During active therapy, total exer-
cise time, time to onset of angina, and 1 mm ST segment
depression were significantly greater on amlodipine/atenolol
(time to 1 mm ST segment depression 520 s on amlodipine/
atenolol vs. 478 s on diltiazem (Adizem XL)/isosorbide
5-mononitrate, p  0.05). During the drug-free day, these
measures were again significantly greater in patients who
had been on amlodipine/atenolol (502 s after amlodipine/
Figure 2. Ambulatory ECG monitoring during phase 2 (monotherapy). Both amlodipine and diltiazem (Adizem XL) reduced ischemic events, but there
was a significantly better effect in the amlodipine-treated patients after omission of a single drug dose (see text). *p  0.002 between amlodipine and
diltiazem (Adizem XL) withdrawal.
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atenolol vs. 434 s after diltiazem [Adizem XL]/isosorbide
5-mononitrate, p  0.002).
ANGINA DIARIES. Both amlodipine and diltiazem (Adizem
XL) monotherapy resulted in highly significant reduction in
both angina attacks and nitroglycerin consumption (p 
0.0001). Both combination regimes were significantly better
at reducing symptoms than monotherapy (p 0.0001). The
amlodipine/atenolol combination patients had lower nitro-
glycerin consumption than those receiving diltiazem
(Adizem XL)/isosorbide 5-mononitrate (p  0.03) with a
nonsignificant reduction in angina (p 0.10) (Figs. 4A and
4B).
HEART RATE AND BP. At the end of the monotherapy phase
there was a modest reduction in systolic and diastolic BP for
both amlodipine and diltiazem (Adizem XL) treatments.
The reduction from baseline in systolic BP was 5.84 (p 
0.0001) and 0.20 (p  ns) mm Hg for amlodipine and
diltiazem (Adizem XL) treatments, respectively. The cor-
responding diastolic BP changes in3.01 (p 0.0005) and
1.74 (p ns) mm Hg. Addition of atenolol to amlodipine
also produced a significant reduction, whereas addition of
isosorbide 5-mononitrate to diltiazem (Adizem XL) re-
sulted in a nonsignificant reduction in BP. The change from
baseline in systolic BP was11.32 (p 0.0001) and2.43
(p  ns) mm Hg for amlodipine and atenolol and diltiazem
(Adizem XL) and isosorbide 5-mononitrate treatments,
respectively. The corresponding diastolic BP changes are
8.07 (p  0.0001) and 0.71 (p  ns) mm Hg. There
was virtually no change in 24-h heart rate during amlodip-
ine monotherapy (with no reflex tachycardia) and there was
a modest reduction on diltiazem (Adizem XL) (0.97
beats/min). Atenolol produced the anticipated marked re-
duction in 24-h heart rate (11.04 beats/min), whereas
addition of 5-mononitrate had a smaller effect (1.16
beats/min).
ADVERSE EVENTS. During the monotherapy phase 22
(17%) amlodipine and 27 (21%) diltiazem (Adizem XL)
patients reported adverse events. Two (1.64%) amlodipine-
treated and four (3.3%) diltiazem (Adizem XL)-treated
patients discontinued therapy because of treatment-
emergent adverse events.
During the combination phase, 28 (23%) amlodipine/
atenolol and 38 (31%) diltiazem (Adizem XL)/5-
mononitrate patients reported adverse events, and one and
three patients discontinued therapy for each group, respec-
tively. The most frequent events were edema (12.5% in the
Figure 3. Circadian pattern of transient ischemia during active therapy and after drug withdrawal. Drug monotherapy phase (A) and combination phase (B).
922 Deanfield et al. JACC Vol. 40, No. 5, 2002
Medical Treatment of Myocardial Ischemia September 4, 2002:917–25
amlodipine group and 4.1% in the diltiazem [Adizem XL]
group) and headache (7.0% in the amlodipine group and
20.5% in the diltiazem [Adizem XL] group).
DISCUSSION
The CAPE II trial has shown the efficacy and tolerability of
once-daily monotherapy with long-acting calcium channel
blockers for the treatment of symptomatic and asymptom-
atic myocardial ischemia in patients with stable CAD. The
anti-ischemic effects were demonstrated by both ambulatory
monitoring and exercise testing and supported by reduction
in angina and sublingual nitroglycerin consumption. There
was an incremental benefit from addition of a second class
of drug in combination therapy and the amlodipine/atenolol
combination proved superior to diltiazem (Adizem XL)/
isosorbide 5-mononitrate.
Amlodipine and diltiazem (Adizem XL) showed compa-
rable efficacy in regular dosing, but the effect on myocardial
ischemia of omission of even a single dose was very different.
Amlodipine proved superior, with maintenance of its anti-
ischemic active over 24 h after dose omission, whereas the
benefits of diltiazem (Adizem XL) were markedly reduced
within a few hours. This is likely to be relevant in the
clinical setting, where patients often take their medication at
irregular intervals or omit doses completely.
In CAPE II, subjective and objective measurements were
used to evaluate treatment effects. Angina is known to
underestimate myocardial ischemia and ambulatory ST
segment monitoring permits the assessment of the pattern
and activity of ischemia during normal daily life in patients
with coronary disease (1,2). The presence of transient
myocardial ischemia during ambulatory monitoring confers
an independent risk of subsequent cardiovascular events
(10,11). Exercise testing was also performed, permitting
evaluation of therapy on ischemia provoked in a controlled
environment. The exercise end points have been widely used
both to detect ischemia and stratify risk (9). The patho-
physiology of myocardial ischemia during exercise testing
and during ambulatory monitoring is likely to differ, and the
use of both objective measurements in CAPE II afforded
Figure 4. Angina attacks (A) and nitroglycerin consumption (B) during monotherapy and combination therapy. Both amlodipine and diltiazem (Adizem
XL) reduced angina and nitroglycerin consumption (p  0.0001). Nitroglycerin consumption was significantly lower in patients receiving amlodipine/
atenolol. *p  0.02.
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the opportunity to examine systematically, the impact of
widely used classes of anti-ischemic agents as monotherapy
and in combination in these two settings. The response of
ischemia during ambulatory monitoring and exercise testing
proved very consistent in the two phases of the trial, both for
efficacy and for the response to drug withdrawal.
The first CAPE trial had shown a benefit of addition of
amlodipine to patients’ background medical therapy but did
not examine the impact of monotherapy (5). In CAPE II,
both amlodipine and diltiazem (Adizem XL) were very
effective when given once daily, in contrast to the results of
earlier studies using short acting first-generation dihydro-
pyridine calcium channel blockers (6). Both agents achieve
stable plasma levels over 24 h and are indicated for once-
daily treatment of angina pectoris. They differ importantly,
however, in the means by which this is achieved, and this is
likely to be the explanation for the potentially important
clinical difference demonstrated when the impact on isch-
emia control was examined after omission of a single dose of
a drug. Amlodipine has long duration of action, with a
plasma elimination half-life of 35 to 50 h. In contrast,
diltiazem (Adizem XL) relies on a delivery system to
maintain once-daily therapeutic effect for the intrinsically
short-acting agent, and blood levels fall rapidly after dose
omission. The benefits on ischemia/angina, both in ambu-
latory monitoring and exercise testing, were largely main-
tained in those who had been receiving amlodipine, whereas
there was return to levels of ischemia seen at baseline within
hours of omission of diltiazem (Adizem XL). It is widely
recognized that patients’ compliance with prescribed med-
ical regimes is often poor. The different response to omis-
sion of amlodipine to that of short-acting agents with
extended delivery systems has been shown to affect control
of blood pressure in hypertensive patients (12). Our findings
in CAPE II suggest a similarly important benefit for
amlodipine in the control of myocardial ischemia in patients
with coronary disease. Effective therapy during the first few
hours of the day may be particularly important in view of the
peak incidence of ischemia and the increased risk of cardio-
vascular morbidity and mortality from MI, stroke, and
sudden death during this period (13). The use of amlodip-
ine, especially with a long-acting beta-blocker, is likely to
provide the most consistent reduction of myocardial isch-
emia in clinical practice.
Patients in CAPE II were recruited from 30 centers in 13
countries. The entry criteria were not restrictive, and ap-
proximately half the screened patients were randomized, a
higher proportion than in most previous studies using
ambulatory ECG monitoring (5,14). As a result, the bene-
ficial effects of the treatment regimes in CAPE II are likely
to be widely applicable to the population of patients with
angina and coronary disease. Both men and women were
included. The trial was not designed to compare responses
in the two genders, however, and no differences were noted.
Critique of study design. Each patient underwent 72 h of
ambulatory monitoring on three occasions, a longer period
than in most, if not all, previous trials. The purpose was not
to improve detection or quantification of transient myocar-
dial ischemia, but to study the effect of omission of therapy
for a single day on the background of stable drug dosing
regimes, using both monotherapy and combination of
drugs. Thus, active therapy was evaluated over 48 h, as in
the first CAPE trial. An excellent quality of ECG signal
was obtained even on the third day of monitoring, and
patients tolerated the extended period well. This has impli-
cations for the design of future trials using ambulatory
ischemic end points. Both ambulatory ECG monitoring
and exercise testing were read centrally. It is noteworthy
that no problems were encountered in communication
among clinical sites in 13 countries and the core laboratories
both for eligibility and transmission of findings of potential
clinical relevance.
Clinical implications. The CAPE II findings demon-
strated excellent symptomatic improvement and ischemia
reduction with medical therapy using single agents and, in
particular, with combination therapy. The prognostic sig-
nificance of ischemic activity of patients with coronary
disease has been demonstrated (10,11), but the benefit of
relief transient ischemia, both with medical therapy and
angioplasty, remains controversial (15). Reduction in mor-
bidity and mortality may require the use of agents that target
the disturbed vascular biology of atherosclerotic arteries
known to contribute to inflammation, vasoconstriction,
thrombosis, and plaque instability (16,17). Angiotensin-
converting enzyme inhibitors and amlodipine have been
shown to affect favorably endothelial function (18), and
clinical trials have indicated benefits on the arterial wall (19)
and clinical events (18,19). Further studies are ongoing to
examine the impact of such agents alone and in combination
on the activity of ischemia, disease progression, and morbid
events, and the results will be of great interest in determin-
ing optimal medical therapy in coronary disease. The
CAPE II study provides firm evidence for the clinical
benefit of medical therapy for angina and ischemia and
supports the use of the intrinsically long-acting calcium
channel blocker amlodipine, alone or with a beta-blocker.
The maintained efficacy of amlodipine in irregular dosing
confers an advantage in the clinical setting over short-acting
drugs, even when they are used with extended-release
delivery systems.
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